Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Unity Biotechnology, Inc. - Common Stock (NQ:UBX)

0.9601 -0.1099 (-10.27%)
Streaming Delayed Price Updated: 1:25 PM EDT, May 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Unity Biotechnology, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
UNITY Biotechnology Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME
From Unity Biotechnology, Inc.
Via GlobeNewswire
Visa To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
UBX Stock Earnings: Unity Biotechnology Beats EPS for Q4 2023
UBX stock results show that Unity Biotechnology beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
From Unity Biotechnology, Inc.
Via GlobeNewswire
Analyst Ratings for Unity Biotechnology
Via Benzinga
The Latest Analyst Ratings for Unity Biotechnology
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision Loss
From Unity Biotechnology, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Where Unity Biotechnology Stands With Analysts
Via Benzinga
Recap: Unity Biotechnology Q1 Earnings
Via Benzinga
Where Unity Biotechnology Stands With Analysts
Via Benzinga
UNITY Biotechnology Doses First Patients in Phase 2 ASPIRE Study of UBX1325 in DME
Topline 16-week data expected in the fourth quarter of 2024 
From Unity Biotechnology, Inc.
Via GlobeNewswire
Unity Biotechnology Upgraded - Analyst Highlights Cash Strength & Execution
Wedbush analyst Andreas Argyrides upgraded the shares of Unity Biotechnology Inc (NASDAQ: UBX) from Neutral to Outperform and 
Via Benzinga
UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business Updates
From Unity Biotechnology, Inc.
Via GlobeNewswire
UNITY Biotechnology Announces Exercise of Warrants for $4.38 Million in Gross Proceeds
From Unity Biotechnology, Inc.
Via GlobeNewswire
Are Longevity Stocks the Next Trillion-Dollar Industry? 3 Anti-Aging Picks
Here are the best longevity stocks to consider. Each stock listed comes with their unique reasons to buy them. 
Via InvestorPlace
UNITY Biotechnology Announces 48-Week Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration
From Unity Biotechnology, Inc.
Via GlobeNewswire
UNITY Biotechnology, Inc. Reports Second Quarter 2023 Financial Results and Business Updates
From Unity Biotechnology, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For June 26, 2023
Via Benzinga
UNITY Announces Design of Phase 2b ASPIRE Study Evaluating UBX1325 in Diabetic Macular Edema (DME)
From Unity Biotechnology, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For May 31, 2023
Via Benzinga
UNITY Biotechnology, Inc. Reports First Quarter 2023 Financial Results and Business Updates
From Unity Biotechnology, Inc.
Via GlobeNewswire
Unity Touts Positive Data From Diabetic Macular Edema Study, Plans Head-To-Head Study With Regeneron's Eylea
Via Benzinga
UNITY Biotechnology Announces Positive 48-Week Results from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
From Unity Biotechnology, Inc.
Via GlobeNewswire
UNITY Biotechnology to Host Program Update on BEHOLD, the Phase 2 Clinical Trial of UBX1325 in Patients with Diabetic Macular Edema
Program Update with retinal expert and senior clinical advisor Robert B. Bhisitkul, M.D., Ph.D., to be held on Monday, April 24 at 5:00 a.m. PT/8:00 a.m. ET 
From Unity Biotechnology, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 81 companies hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 76 companies set new 52-week lows. 
Via Benzinga
Why Shift Technologies Shares Are Trading Lower By 15%; Here Are 20 Stocks Moving Premarket
Gainers LogicMark, Inc. (NASDAQ: LGMK) shares rose 36.7% to $0.1914 in pre-market trading after the company reported strong revenue and margin growth for the year ended 2022. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  During Tuesday, 95 stocks hit new 52-week lows. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback